Elektronische Zigaretten – Schadensminimierung oder Schadensverlängerung?

Zusammenfassung

Der Beitrag befasst sich mit der Frage, ob Elektronische Zigaretten (E-Zigaretten) den erwiesenen Schaden des Rauchens von Tabakprodukten minimieren können oder zu einer Schadensverlängerung führen. Während das britische Royal College of Physicians Rauchern E-Zigaretten als Substitut für Tabakprodukte empfiehlt, rät die Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin Rauchern von der Nutzung der E-Zigarette ab. Drei Hypothesen liegen der Schadensminimierungsstrategie zugrunde. Hypothese 1: Es wird davon ausgegangen, dass E-Zigaretten gesundheitlich weniger Schaden anrichten als Tabakzigaretten. Hypothese 2: Es wird postuliert, dass Raucher motiviert sind, von konventionellen Zigaretten auf E-Zigaretten umzusteigen. Hypothese 3: Es wird vermutet, dass E-Zigaretten ein nebenwirkungsarmes, effektives Mittel zum Rauchstopp sind. Obwohl die langfristigen gesundheitlichen Folgen des E-Zigarettenkonsums nach wie vor unbekannt sind, mehren sich die Befunde, dass E-Zigaretten toxisch wirken, schädlich für das Herz-Kreislauf-System, die Gesundheit der Atemwege und möglicherweise krebserregend sind. Bevölkerungsrepräsentative epidemiologische Erhebungen zeigen, dass drei Viertel aller aktuellen E-Zigarettennutzer in Deutschland gleichzeitig Tabak rauchen. E-Zigaretten haben in wenigen randomisierten klinischen Studien im Vergleich zu Nikotinersatzprodukten höhere Erfolgsraten. Als frei verkäufliche Konsumprodukte unter Realbedingungen findet sich in einer Vielzahl von Studien kein Vorteil für E-Zigaretten. Zudem verlängern E-Zigaretten im Vergleich zu Nikotinersatzprodukten die Nikotinabhängigkeit. Die Hypothesen der Schadensminimierungsstrategie mittels E-Zigaretten müssen nach derzeitigem Kenntnisstand als widerlegt angesehen werden. Daher erscheint es ethisch nicht unproblematisch, wenn Ärzte ihren Patienten E-Zigaretten als Substitut zum Rauchen empfehlen.

Abstract

This paper deals with the question of whether electronic cigarettes (e-cigarettes) can minimize the proven harm of smoking tobacco or may lead to a long-term harm. While the British Royal College of Physicians recommends smokers to use e-cigarettes as a substitute for tobacco products, the German Society for Pneumology and Respiratory Medicine advises smokers against using e-cigarettes. The harm reduction strategy is based on three hypotheses. Hypothesis 1: It is assumed that e-cigarettes cause less damage to health than tobacco cigarettes. Hypothesis 2: It is postulated that smokers are motivated to switch from conventional cigarettes to e-cigarettes. Hypothesis 3: It is assumed that e-cigarettes are an effective means for quitting smoking with few side effects. Although the long-term health consequences of e-cigarette use remain unknown, there is increasing evidence that e-cigarettes are toxic, harmful to cardiovascular system, respiratory health and potentially carcinogenic. Population-representative epidemiological surveys have shown that three-quarters of all current e-cigarette users in Germany smoke tobacco at the same time. In a few randomized clinical trials, e-cigarettes showed higher success rates compared to nicotine replacement products. As over-the-counter consumer products, a large number of studies have found no advantage for e-cigarettes under real conditions. In addition, e-cigarettes prolong nicotine dependence compared to nicotine replacement products. According to the current state of knowledge, the hypotheses behind the harm minimization strategy using e-cigarettes must be regarded as refuted. It therefore appears ethically problematic when doctors recommend e-cigarettes to their patients as a substitute for smoking.

Schlüsselwörter

Rauchen - E-Zigaretten - Schadensminimierung

Keywords

smoking - e-cigarettes - harm reduction

Publikationsverlauf

Eingereicht: 30. Januar 2023

Angenommen nach Revision: 09. Februar 2023

Artikel online veröffentlicht:
28. März 2023

• Literatur

• 1 GBD 2019 Tobacco Collaborators. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet 2021; 397: 2337-2360
• 2 Mons U, Kahnert S. Neuberechnung der tabakattributablen Mortalität – Nationale und regionale Daten für Deutschland. Gesundheitswesen 2019; 81: 24-33
• 3 Royal College of Physicians. Smoking and health 2021: a coming of age for tobacco control?. London: RCP; 2021
• 4 McKee M. Evidence and E-Cigarettes: Explaining English Exceptionalism. Am J Public Health 2019; 109: 965-966
• 5 WHO. WHO report on the global tobacco epidemic 2021: addressing new and emerging products. Geneva: WHO; 2021
• 6 Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin in Zusammenarbeit mit medizinischen Fachgesellschaften und Organisationen. Empfehlungen zum Umgang mit der elektronischen Zigarette (E-Zigarette). Pneumologie 2022; 76: 473-478
• 7 Smith MR, Clark B, Lüdicke F. et al. Evaluation of the Tobacco Heating System 2.2. Part 1: Description of the system and the scientific assessment program. Regul Toxicol Pharmacol 2016; 81 (Suppl. 02) S17-S26
• 8 Nutt DJ, Phillips LD, Balfour D. et al. Estimating the harms of nicotine-containing products using the MCDA approach. Eur Addict Res 2014; 20: 218-225
• 9 McNeill A, Brose LS, Calder R. et al. E-cigarettes: an evidence update. A report commissioned by Public Health England. London: Public Health England; 2015
• 10 Eissenberg T, Bhatnagar A, Chapman S. et al. Invalidity of an Oft-Cited Estimate of the Relative Harms of Electronic Cigarettes. Am J Public Health 2020; 110: 161-162
• 11 Murray R, Evison M, Callister M. Nicotine or tobacco abstinence? A reply to Hanewinkel et al. Eur Respr Rev 2022; 31: 220089
• 12 Hanewinkel R, Niederberger K, Pedersen A. et al. Reply to: “Nicotine or tobacco abstinence?”. Eur Respir Rev 2022; 31: 220158
• 13 Pipe AL, Mir H. E-Cigarettes Reexamined: Product Toxicity. Can J Cardiol 2022; 38: 1395-1405
• 14 Neczypor EW, Mears MJ, Ghosh A. et al. E-Cigarettes and Cardiopulmonary Health: Review for Clinicians. Circulation 2022; 145: 219-232
• 15 McConnell R, Barrington-Trimis JL, Wang K. et al. Electronic Cigarette Use and Respiratory Symptoms in Adolescents. Am J Respir Crit Care Med 2017; 195: 1043-1049
• 16 Jonas A. Impact of vaping on respiratory health. Bmj 2022; 378: e065997
• 17 Wills TA, Soneji SS, Choi K. et al. E-cigarette use and respiratory disorders: an integrative review of converging evidence from epidemiological and laboratory studies. Eur Respir J 2021; 57
• 18 Farber HJ, Conrado Pacheco Gallego M, Galiatsatos P. et al. Harms of Electronic Cigarettes: What the Healthcare Provider Needs to Know. Ann Am Thorac Soc 2021; 18: 567-572
• 19 Asfar T, Jebai R, Li W. et al. Risk and safety profile of electronic nicotine delivery systems (ENDS): an umbrella review to inform ENDS health communication strategies. Tob Control 2022;
• 20 The Lancet. E-cigarettes: time to realign our approach?. Lancet 2019; 394: 1297
• 21 Banks E, Yazidjoglou A, Brown S. et al. Electronic cigarettes and health outcomes: systematic review of global evidence. Canberra: National Centre for Epidemiology and Population Health; 2022
• 22 Pope 3rd CA, Burnett RT, Krewski D. et al. Cardiovascular mortality and exposure to airborne fine particulate matter and cigarette smoke: shape of the exposure-response relationship. Circulation 2009; 120: 941-948
• 23 Tverdal A, Bjartveit K. Health consequences of reduced daily cigarette consumption. Tob Control 2006; 15: 472-480
• 24 Jarvis MJ. Why people smoke. Bmj 2004; 328: 277-279
• 25 Dawkins L, Cox S, Goniewicz M. et al. ‘Real-world’ compensatory behaviour with low nicotine concentration e-liquid: subjective effects and nicotine, acrolein and formaldehyde exposure. Addiction 2018; 113: 1874-1882
• 26 OʼConnor R, Durkin SJ, Cohen JE. et al. Thoughts on neologisms and pleonasm in scientific discourse and tobacco control. Tobacco Control 2021; 30: 359-360
• 27 Pisinger C, Godtfredsen N, Bender AM. A conflict of interest is strongly associated with tobacco industry-favourable results, indicating no harm of e-cigarettes. Prev Med 2019; 119: 124-131
• 28 Sreeramareddy CT, Acharya K, Manoharan A. Electronic cigarettes use and ‘dual use’ among the youth in 75 countries: estimates from Global Youth Tobacco Surveys (2014–2019). Sci Rep 2022; 12: 20967
• 29 Coleman SRM, Piper ME, Byron MJ. et al. Dual Use of Combustible Cigarettes and E-cigarettes: a Narrative Review of Current Evidence. Curr Addict Rep 2022; 9: 353-362
• 30 Kotz D, Böckmann M, Kastaun S. The Use of Tobacco, E-Cigarettes, and Methods to Quit Smoking in Germany. Dtsch Arztebl Int 2018; 115: 235-242
• 31 Pisinger C, Rasmussen SKB. The Health Effects of Real-World Dual Use of Electronic and Conventional Cigarettes versus the Health Effects of Exclusive Smoking of Conventional Cigarettes: A Systematic Review. Int J Environ Res Public Health 2022; 19
• 32 Beard E, Brown J, Michie S. et al. Is prevalence of e-cigarette and nicotine replacement therapy use among smokers associated with average cigarette consumption in England? A time-series analysis. BMJ Open 2018; 8: e016046
• 33 Hedman L, Galanti MR, Ryk L. et al. Electronic cigarette use and smoking cessation in cohort studies and randomized trials: A systematic review and meta-analysis. Tob Prev Cessat 2021; 7: 62
• 34 Chen R, Pierce JP, Leas EC. et al. Effectiveness of e-cigarettes as aids for smoking cessation: evidence from the PATH Study cohort, 2017–2019. Tob Control 2022;
• 35 Barufaldi LA, Guerra RL, de Albuquerque RCR. et al. Risk of smoking relapse with the use of electronic cigarettes: A systematic review with meta-analysis of longitudinal studies. Tob Prev Cessat 2021; 29: 29
• 36 Pierce JP, Chen R, Kealey S. et al. Incidence of Cigarette Smoking Relapse Among Individuals Who Switched to e-Cigarettes or Other Tobacco Products. JAMA Netw Open 2021; 4: e2128810
• 37 Pound CM, Zhang JZ, Kodua AT. et al. Smoking cessation in individuals who use vaping as compared with traditional nicotine replacement therapies: a systematic review and meta-analysis. BMJ Open 2021; 11: e044222
• 38 Hartmann-Boyce J, Lindson N, Butler AR. et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev 2022; 11: Cd010216
• 39 Russel C, McKeganey N, Katsampouris E. et al. A randomised community-based trial of a closed-system pod e-vapour product and nicotine replacement therapy for cigarette abstinece and reduction. Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting February 24–27 2021. virtual:PH-353 p230 2021.
• 40 Batra A, Kiefer F, Andreas S. et al. S3-Leitlinie „Rauchen und Tabakabhängigkeit: Screening, Diagnostik und Behandlung“. SUCHT 2021; 67: 55-75
• 41 Nationale Versorgungs Leitlinien. NVL COPD, 2. Auflage. Zugriff am 28. Februar 2023 unter: https://wwwleitliniende/themen/copd/2-auflage 2021
• 42 Bals R, Boyd J, Esposito S. et al. Electronic cigarettes: a task force report from the European Respiratory Society. Eur Respir J 2019; 53
• 43 Ferkol TW, Farber HJ, La Grutta S. et al. Electronic cigarette use in youths: a position statement of the Forum of International Respiratory Societies. Eur Respir J 2018; 51
• 44 Herbst RS, Hatsukami D, Acton D. et al. Electronic Nicotine Delivery Systems: An Updated Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology. Clin Cancer Res 2022; 28: 4861-4870
• 45 McDonald CF, Jones S, Beckert L. et al. Electronic cigarettes: A position statement from the Thoracic Society of Australia and New Zealand. Respirology 2020; 25: 1082-1089
• 46 Signes-Costa J, de Granda-Orive JI, Ramos Pinedo Á. et al. Official Statement of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) on Electronic Cigarettes and IQOS. Arch Bronconeumol (Engl Ed) 2019; 55: 581-586
• 47 Society for Adolescent Health and Medicine. Protecting Youth From the Risks of Electronic Cigarettes. J Adolesc Health 2020; 66: 127-131
• 48 Benowitz NL. Nicotine addiction. N Engl J Med 2010; 362: 2295-2303
• 49 Faure P, Tolu S, Valverde S. et al. Role of nicotinic acetylcholine receptors in regulating dopamine neuron activity. Neuroscience 2014; 282: 86-100
• 50 Solingapuram Sai KK, Zuo Y, Rose JE. et al. Rapid Brain Nicotine Uptake from Electronic Cigarettes. J Nucl Med 2020; 61: 928-930
• 51 Hanewinkel R, Niederberger K, Pedersen A. et al. E-cigarettes and nicotine abstinence: a meta-analysis of randomised controlled trials. Eur Respir Rev 2022; 31: 210215
• 52 Butler AR, Lindson N, Fanshawe TR. et al. Longer-term use of electronic cigarettes when provided as a stop smoking aid: Systematic review with meta-analyses. Prev Med 2022; 165: 107182
• 53 Hartmann-Boyce J, Chepkin SC, Ye W. et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev 2018; 5: Cd000146
• 54 Stead LF, Buitrago D, Preciado N. et al. Physician advice for smoking cessation. Cochrane Database Syst Rev 2013; 2013: Cd000165
• 55 Hanewinkel R. Gesundheitsrisiken der E-Zigarette. MMW Fortschr Med 2023; 165: 62-63